Econometric analyses, when done correctly, can provide useful evaluations of policies and strategies that have been implemented, or are being contemplated, by public and private sector actors. We have extensive capabilities in econometric modelling for litigation support, with virtually unlimited capacity to handle large datasets and complicated statistical problems. We have likewise conducted econometric analyses for clients outside of the litigation area, such as outcome analyses of open-label extensions for (Phase IV) clinical trials, and economic outcome analyses adjunct to Phase III clinical trials.